Monopar Therapeutics: Progress in Radiopharmaceutical Research and Development of ALXN1840, Analyst Support, and Index Inclusion!
Reading Time: 3 minutes
Monopar Therapeutics Inc. (MNPR) has made significant progress in the development of its radiopharmaceutical pipeline in recent times. The company is currently conducting two Phase 1 studies in Australia: one with MNPR-101-Zr for imaging and dosimetry, and a therapeutic study with MNPR-101-Lu for the treatment of advanced solid tumors. Both programs target the urokinase plasminogen activator receptor (uPAR), which is overexpressed in aggressive cancers such as pancreatic, ovarian, triple-negative breast, and colorectal cancer. Furthermore, MNPR-101-Ac...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
